Jakub Svoboda, MD, reports on recent developments in the management of advanced Hodgkin lymphoma (HL), with a particular focus upon the elimination of bleomycin as a component of combined therapy in the latter stages of treatment, and the application of the antibody-drug conjugate brentuximab vedotin as a potential curative in subsets of patients who relapse post-autotransplant. Also includes a review of ongoing clinical trials in HL at Penn Medicine’s Comprehensive Center for Hodgkin Lymphoma

Related Links: